Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective, Multicenter, Real-world Observational Study of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma.

NCT07354282 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT07354282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07354282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective, Multicenter, Real-world Observational Study of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma.
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Observational
Overall status
Completed
Start date
May 13, 2025
Completion date
August 7, 2025
Enrollment
200 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer metastatic